Status:
ACTIVE_NOT_RECRUITING
Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study
Lead Sponsor:
Qianfoshan Hospital
Conditions:
Prostate Cancers
Eligibility:
MALE
18+ years
Brief Summary
Prostate cancer (PC) is the most common malignancy in the male genitourinary system. In China, both the incidence and mortality rates of PC have shown a significant upward trend in recent years. Chine...
Eligibility Criteria
Inclusion
- \- 1. Patients with histologically confirmed prostate cancer (PC) deemed suitable for endocrine therapy (excluding neoadjuvant endocrine therapy).
- 2\. At least 18 years old 3. Prescribed 3.6 mg goserelin every 4 weeks as monotherapy or in combination with anti-androgen therapy.
Exclusion
- 1\. Hypersensitivity to LHRH, its analogs, or any component of goserelin. 2. Previous or concurrent hormone therapy, except for conventional anti-androgen therapy administered within 2 weeks before goserelin treatment.
- 3\. Diagnosis or suspicion of hormone-resistant PC, history of hypophysectomy, adrenalectomy, or pituitary lesions.
- Scheduled for radical radiotherapy (adjuvant radiotherapy post-radical prostatectomy \[RP\] combined with goserelin is permitted) or planned neoadjuvant hormone therapy prior to RP.
Key Trial Info
Start Date :
April 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06929884
Start Date
April 2 2020
End Date
May 1 2025
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China